Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

Wendtner Cm,M Ritgen,Cd Schweighofer,G. Fingerle-Rowson,H Campe,G Jäger,B.F Eichhorst,R Busch,H. Diem,Andreas Engert,S. Stilgenbauer,H Döhner,M Kneba,Bertold Emmerich,Michael Hallek

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

2004

Wendtner Cm
M Ritgen
Cd Schweighofer
G. Fingerle-Rowson
H Campe
G Jäger
B.F Eichhorst
R Busch
H. Diem
Andreas Engert
S. Stilgenbauer
H Döhner
M Kneba
Bertold Emmerich
Michael Hallek

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

Keywords:

Chronic lymphocytic leukemia
Minimal residual disease
Clinical trial
Oncology
Cancer research
Progression-free survival
Hematology
Alemtuzumab
Pulmonary tuberculosis
Fludarabine
Medicine
Surgery
Internal medicine
Leukemia
Gastroenterology
Cyclophosphamide
Ganciclovir
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

263

Citations